Background

Emerging hypotheses in the pathophysiology of major depressive disorder (MDD) indicate the role of neurotrophic factors and inflammation. This study assessed the association between therapeutic response of bupropion and serum brain-derived neurotrophic factor (BDNF) and tumour necrosis factor-α (TNF-α) levels in patients with MDD.

Methods

Thirty patients (aged 18 to 60 years) with MDD diagnosed by DSM-5 criteria, with Hamilton Depression Rating scale (HAM-D) score ≥ 20 were included in the study. Patients were given bupropion sustained release (SR) in the doses of 150 mg once daily. All patients were followed up for 12 weeks.

Results

HAM-D score at the start of the treatment was 25.57 ± 1.85 which significantly reduced to 10.8 ± 4.24 at 12 weeks of treatment. The serum BDNF level increased significantly (p < 0.05) from 2.42 ± 0.19 ng/ml to 2.97 ± 0.10 ng/ml and the levels of serum TNF-α reduced significantly (p < 0.05) from 4.45 ± 0.95 pg/ml to 2.11 ± 0.84 pg/ml at 12 weeks of treatment, in responders to treatment.

Conclusion

The results of our study suggest that bupropion SR monotherapy is effective and well tolerated in MDD patients with moderate to severe depression, and its therapeutic efficacy is accompanied by an increase in serum BDNF levels and a decrease in serum TNF-α levels.

中文翻译：

---

安非他酮单药治疗可改变重度抑郁症患者的神经营养和炎症指标

背景

重度抑郁症（MDD）病理生理学中的新假说表明了神经营养因子和炎症的作用。这项研究评估了安非他酮与血清脑源性神经营养因子（BDNF）和肿瘤坏死因子-α（TNF-α）水平的治疗反应之间的关联。

方法

研究纳入了30例年龄18至60岁，通过DSM-5标准诊断为MDD且汉密尔顿抑郁量表（HAM-D）得分≥20的患者。每天一次给患者服用安非他酮缓释剂（SR），剂量为150 mg。所有患者均接受了12周的随访。

结果

治疗开始时的HAM-D评分为25.57±1.85，在治疗12周时显着降低至10.8±4.24。血清BDNF水平从2.42±0.19 ng / ml显着增加（p <0.05）至2.97±0.10 ng / ml，血清TNF-α水平从4.45±0.95 pg / ml显着降低（p <0.05）至2.11±治疗12周时，对治疗有反应者为0.84 pg / ml。

结论

我们的研究结果表明，安非他酮SR单一疗法在中度至重度抑郁的MDD患者中有效且耐受性良好，并且其治疗功效伴随血清BDNF水平升高和血清TNF-α水平降低。